Skip to main content

Iron Toxicity Treatment Recalled

October 16, 2017

Pfizer Inc. is recalling single-use, 10-mL vials of deferoxamine mesylate for injection, USP, 500 mg per vial, for subcutaneous, intramuscular or intravenous use (NDC 0409-2336-10), according to the October 11, 2017, US Food and Drug Administration (FDA) Enforcement Report.

The product was out of specification for color, the FDA reported.

Related Content
Gastric acid blockers boost risk of iron deficiency
Iron-deficiency anemia common in both male and female endurance athletes

The recall affects 32,276 vials from lot 51275DD, which has an expiration date of September 1, 2017. The vials, packaged by Hospira Inc., were distributed across the United States.

Pfizer initiated the voluntary recall July 12, 2017. On October 3, 2017, the FDA designated it a Class III recall, suggesting exposure to the affected product will not cause harm.

Deferoxamine mesylate for injection is a prescription medication used to treat iron toxicity.

Jolynn Tumolo

Back to Top